Krystal Biotech (NASDAQ:KRYS) Shares Down 6.5% – Time to Sell?

Krystal Biotech, Inc. (NASDAQ:KRYSGet Free Report) shares traded down 6.5% during trading on Thursday . The stock traded as low as $175.00 and last traded at $175.00. 168,022 shares changed hands during mid-day trading, a decline of 48% from the average session volume of 320,485 shares. The stock had previously closed at $187.12.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on KRYS shares. Stifel Nicolaus increased their target price on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Chardan Capital restated a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a research note on Thursday. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Citigroup boosted their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech has an average rating of “Buy” and a consensus price target of $206.67.

Get Our Latest Stock Report on KRYS

Krystal Biotech Trading Down 5.6 %

The firm’s 50 day moving average price is $181.27 and its two-hundred day moving average price is $184.88. The company has a market capitalization of $4.71 billion, a price-to-earnings ratio of 92.45 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYSGet Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same period in the previous year, the company posted ($0.67) EPS. The firm’s revenue for the quarter was up 879.9% compared to the same quarter last year. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Key Financial Inc acquired a new stake in Krystal Biotech in the 2nd quarter worth about $28,000. Blue Trust Inc. raised its position in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech during the third quarter worth approximately $40,000. Values First Advisors Inc. bought a new position in Krystal Biotech during the 3rd quarter worth $53,000. Finally, Quest Partners LLC acquired a new position in Krystal Biotech in the 2nd quarter valued at $71,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

(Get Free Report)

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Further Reading

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.